Formation of Immunochemical Advanced Glycosylation End Products Precedes and Correlates With Early Manifestations of Renal and Retinal Disease in Diabetes
The DOI matches its Crossref record.
Abstract
Elevated levels of advanced glycosylation end products (AGEs) have been found in multiple tissues in association with diabetic vascular complications and during the microalbuminuric phase of diabetic nephropathy. In this study, we have used an AGE-specific enzyme-linked immunosorbent assay (ELISA) to measure skin AGEs to determine whether elevated levels can be detected before the onset of overt microangiopathy. Subjects with type I diabetes (n = 48) were graded for the degree of nephropathy (normal [23], microalbuminuria [12], or macroalbuminuria [12]) and retinopathy (none [13], background [20], or proliferative [15]). Subgroups with a premicroalbuminuric phase of albumin excretion (≤28 mg/24 h, n = 27) or with the earliest stages of retinopathy (n = 27) were identified. A significant increase in tissue AGEs was found as urinary albumin increased during the premicroalbuminuric phase of nephropathy even when the data were adjusted for age and duration of diabetes (P = 0.005). Immunoreactive AGEs also increased as normal renal status advanced to microalbuminuria and macroalbuminuria (P = 0.0001 across groups). Significant elevation of AGEs was also found in association with the earliest stages of clinically evident retinopathy (early background versus minimal grades). In addition, higher AGE levels were found in subjects with proliferative retinopathy when compared with those with less severe retinopathy (P < 0.004 across groups). In contrast, no significant differences were found in tissue AGE levels between groups with or without early retinopathy based on pentosidine or fluorescent AGE measurements, although fluorescent AGEs correlated with albumin excretion. In conclusion, levels of collagen-linked AGEs, when measured by an AGE-specific ELISA, reveal a correlation with preclinical stages of diabetic nephropathy and early retinopathy not indicated by other methods and may prove useful as early markers of microangiopathy in type I diabetes.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cited by
Simple non-invasive assessment of advanced glycation endproduct accumulation
Meerwaldt, R., Graaff, R., Oomen, P. H. N., Links, T. P., Jager, J. J., Alderson, N. L., Thorpe, S. R., Baynes, J. W., Gans, R. O. B., & Smit, A. J. (2004) · Diabetologia · doi:10.1007/s00125-004-1451-2 · Cited by 766
Monnier, V. M., Bautista, O., Kenny, D., Sell, D. R., Fogarty, J., Dahms, W., Cleary, P. A., Lachin, J., & Genuth, S. (1999) · Diabetes · doi:10.2337/diabetes.48.4.870 · Cited by 469
Bolton, W. K., Cattran, D. C., Williams, M. E., Adler, S. G., Appel, G. B., Cartwright, K., Foiles, P. G., Freedman, B. I., Raskin, P., Ratner, R. E., et al. (2004) · American Journal of Nephrology · doi:10.1159/000075627 · Cited by 461
Candido, R., Forbes, J. M., Thomas, M. C., Thallas, V., Dean, R. G., Burns, W. C., Tikellis, C., Ritchie, R. H., Twigg, S. M., Cooper, M. E., et al. (2003) · Circulation Research · doi:10.1161/01.res.0000065620.39919.20 · Cited by 448
Endothelial dysfunction and pathogenesis of diabetic angiopathy
Stehouwer, C. (1997) · Cardiovascular Research · doi:10.1016/s0008-6363(96)00272-6 · Cited by 441
Genuth, S., Sun, W., Cleary, P., Sell, D. R., Dahms, W., Malone, J., Sivitz, W., Monnier, V. M., & for the DCCT Skin Collagen Ancillary Study Group (2005) · Diabetes · doi:10.2337/diabetes.54.11.3103 · Cited by 427
Advanced Glycation end Products, Oxidative Stress and Diabetic Nephropathy
Yamagishi, S.-I., & Matsui, T. (2010) · Oxidative Medicine and Cellular Longevity · doi:10.4161/oxim.3.2.11148 · Cited by 397
AGE, RAGE, and ROS in Diabetic Nephropathy
Tan, A. L. Y., Forbes, J. M., & Cooper, M. E. (2007) · Seminars in Nephrology · doi:10.1016/j.semnephrol.2007.01.006 · Cited by 368
The role of oxidative stress and NF‐κB activation in late diabetic complications
Mohamed, A. K., Bierhaus, A., Schiekofer, S., Tritschler, H., Ziegler, R., & Nawroth, P. P. (1999) · BioFactors · doi:10.1002/biof.5520100211 · Cited by 339
Diabetes and Advanced Glycoxidation End Products
Huebschmann, A. G., Regensteiner, J. G., Vlassara, H., & Reusch, J. E. B. (2006) · Diabetes Care · doi:10.2337/dc05-2096 · Cited by 330
Self-citationGlycation Damage: A Possible Hub for Major Pathophysiological Disorders and Aging
Fournet, M., Bonté, F., & Desmoulière, A. (2018) · Aging and disease · doi:10.14336/ad.2017.1121 · Cited by 291
Advanced glycation end products: A nephrologist's perspective
Raj, D. S. C., Choudhury, D., Welbourne, T. C., & Levi, M. (2000) · American Journal of Kidney Diseases · doi:10.1016/s0272-6386(00)70189-2 · Cited by 290
Skin Autofluorescence Is a Strong Predictor of Cardiac Mortality in Diabetes
Meerwaldt, R., Lutgers, H. L., Links, T. P., Graaff, R., Baynes, J. W., Gans, R. O. B., & Smit, A. J. (2007) · Diabetes Care · doi:10.2337/dc06-1391 · Cited by 287
Negative consequences of glycation
Brownlee, M. (2000) · Metabolism · doi:10.1016/s0026-0495(00)80078-5 · Cited by 284
Shipanova, I. N., Glomb, M. A., & Nagaraj, R. H. (1997) · Archives of Biochemistry and Biophysics · doi:10.1006/abbi.1997.0195 · Cited by 279
Skin Autofluorescence as a Noninvasive Marker of Vascular Damage in Patients With Type 2 Diabetes
Lutgers, H. L., Graaff, R., Links, T. P., Ubink-Veltmaat, L. J., Bilo, H. J., Gans, R. O., & Smit, A. J. (2006) · Diabetes Care · doi:10.2337/dc05-2173 · Cited by 264
Forbes, J. M., Thallas, V., Thomas, M. C., Founds, H. W., Burns, W. C., Jerums, G., & Cooper, M. E. (2003) · The FASEB Journal · doi:10.1096/fj.02-1102fje · Cited by 263
Pathophysiology of the Diabetic Kidney
Vallon, V., & Komers, R. (2011) · Comprehensive Physiology · doi:10.1002/cphy.c100049 · Cited by 259
Involvement of Advanced Glycation End Products in the Pathogenesis of Diabetic Retinopathy
Xu, J., Chen, L.-J., Yu, J., Wang, H.-J., Zhang, F., Liu, Q., & Wu, J. (2018) · Cellular Physiology and Biochemistry · doi:10.1159/000491897 · Cited by 204
Nedić, O., Rattan, S. I. S., Grune, T., & Trougakos, I. P. (2013) · Free Radical Research · doi:10.3109/10715762.2013.806798 · Cited by 162
Adverse effects of dietary glycotoxins on wound healing in genetically diabetic mice
Peppa, M., Brem, H., Ehrlich, P., Zhang, J.-G., Cai, W., Li, Z., Croitoru, A., Thung, S., & Vlassara, H. (2003) · Diabetes · doi:10.2337/diabetes.52.11.2805 · Cited by 153
Yacoub, R., Nugent, M., Cai, W., Nadkarni, G. N., Chaves, L. D., Abyad, S., Honan, A. M., Thomas, S. A., Zheng, W., Valiyaparambil, S. A., et al. (2017) · PLOS ONE · doi:10.1371/journal.pone.0184789 · Cited by 139
Pentosidine and N-Carboxymethyl-Lysine: Biomarkers for Type 2 Diabetic Retinopathy
Ghanem, A. A., Elewa, A., & Arafa, L. F. (2011) · European Journal of Ophthalmology · doi:10.5301/ejo.2010.4447 · Cited by 73
Dorecka, M., Siemianowicz, K., Francuz, T., Garczorz, W., Chyra, A., Klych, A., & Romaniuk, W. (2013) · Pharmacological Reports · doi:10.1016/s1734-1140(13)71069-7 · Cited by 36
“[4] studied tissue deposition of AGE in diabetic patients.”
Background
Metadata
- Authors
- Beisswenger, P. J., Makita, Z., Curphey, T. J., Moore, L. L., Jean, S., Brinck-Johnsen, T., Bucala, R., & Vlassara, H.
- Venue
- Diabetes
- Publisher
- American Diabetes Association
- Published
- 1995-07-01
- Volume
- 44
- Issue
- 7
- Pages
- 824-829
- ISSN
- 0012-1797 (ISSN-L)
- 1939-327X
- OpenAlex
- W1964586920
- Cited by
- 253
- References
- 0
- FWCI
- 6.34
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.